Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weight Loss Products Provide Ample Targets In FDA War On Spiked Supplements

This article was originally published in The Tan Sheet

Executive Summary

FDA finds four weight loss products that contain potentially dangerous undeclared ingredients, including DMAA and sibutramine. The agency also continues to warn about bee pollen with undeclared ingredients.

You may also be interested in...



DoJ Casts Criminal Charge Net For Supplements Making STD Claims

DoJ announces misdemeanor charges against firm warned about making unapproved claims of treating STDs and cancer for products marketed as dietary supplements, while FDA continues finding the banned weight loss drug sibutramine in products.

Protecting DSHEA, Pumping Up Profile Lead Dietary Supplement Industry Priorities For 2015

Executives with AHPA, CRN and NPA comment on hopes for adding supplements to the U.S. nutrition guidelines, on the industry’s regulatory outlook and on legislative priorities amid congressional turnover following the mid-term elections in November.

Protecting DSHEA, Pumping Up Profile Lead Dietary Supplement Industry Priorities For 2015

Executives with AHPA, CRN and NPA comment on hopes for adding supplements to the U.S. nutrition guidelines, on the industry’s regulatory outlook and on legislative priorities amid congressional turnover following the mid-term elections in November.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS107171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel